Key Highlights

  • Shares trading up 13.73% to $1.62 in today's session.
  • Trading Volume reached 4.62 million shares, well above typical levels.
  • The company reported an EPS of negative $0.66.
  • The restructuring is expected to extend the company's cash runway into 2029.

Comprehensive Financial Restructuring Announced

ADC Therapeutics SA (NYSE:ADCT), a Swiss biotech focused on antibody-drug conjugates for blood cancers, announced a comprehensive financial restructuring. The package includes an $86.6 million private Placement with new and existing institutional investors, an amendment removing a $150 million change-of-control payment from its Royalty financing agreement, and a Loan amendment that cuts outstanding term loan principal to $50 million while removing a minimum Liquidity requirement.

Cash Runway Extended Into 2029

The company said the combined moves extend its expected cash runway into 2029, giving it more flexibility to continue funding studies of its approved drug, ZYNLONTA, including ongoing Phase 3 trials in diffuse large B-cell lymphoma and marginal zone lymphoma. Shares rose sharply on the news, suggesting investors welcomed the reduced Financial Risk tied to the company's Debt load.

Elevated Trading Volume Reflects Investor Reaction

Trading volume reached 4.62 million shares, sharply above typical levels, as the stock's EPS of negative $0.66 continues to reflect the company's pre-profitability stage. The restructuring follows a preliminary estimate of approximately $21 million in third-quarter net product Revenue from ZYNLONTA sales.

Outlook: Pipeline Data Expected in Coming Weeks

With its Balance Sheet strengthened, the company said it is approaching key data readouts in its LOTIS-7 and marginal zone lymphoma programs, expected in early November with full presentations in December. These upcoming results may serve as the next catalyst for the stock following today's financing news.